Ben Derman, Assistant Professor at the University of Chicago, shared on X:
“Congratulations to the ENDURANCE investigators on an impactful trial – they should be applauded for running a successful cooperative group phase 3 trial with two randomizations! My thoughts below… ENDURANCE enrolled patients without high-risk disease and without intention for ASCT. The 1st randomization evaluated KRd vs. VRd (no difference in PFS).
The 2nd randomization evaluated 2 years vs indefinite lenalidomide maintenance with OS as the primary endpoint. After 9 years of follow-up, there is no difference in OS! Let’s dive in and take a closer look…”
Title: Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
Authors: Shaji Kumar, Susanna Jacobus, Adam Cohen, Matthias Weiss, Natalie Callander, Avina Singh, Terri Parker, Michael Green, Raymond Thertulien, Benjamin Parsons, Pankaj Kumar, Prashant Kapoor, Aaron Rosenberg, Elie Dib, Daniel Almquist, Jeffrey Zonder, Edward Faber, Zihan Wei, Kenneth Anderson, Sagar Lonial, Paul Richardson, Robert Orlowski, Lynne Wagner, S. Vincent Rajkumar
Read the Full Article.
Other articles featuring Ben Derman on OncoDaily.